Literature DB >> 19122357

Late onset neutropenia and immunoglobulin suppression of the patients with malignant lymphoma following autologous stem cell transplantation with rituximab.

Yasuo Hirayama1, Kyuhei Kohda, Yuichi Konuma, Yasuji Hirata, Hiroyuki Kuroda, Yuko Fujimi, Sayaka Shirao, Masayoshi Kobune, Rishu Takimoto, Takuya Matsunaga, Junji Kato.   

Abstract

BACKGROUND: Recently, decrease of immunoglobulin concentrations or neutrophil counts were reported in some cases several months after administration of rituximab. We examined a number of episodes of late onset neutropenia or immunoglobulin decrease in patients with malignant lymphoma who were in complete remission following autologous transplantation with or without rituximab.
METHOD: Patients with follicular lymphoma and diffuse large B cell lymphoma transplanted with or without rituximab in our institutes were analyzed. Immunoglobulin concentrations and neutrophil counts after transplantation, both with and without rituximab were measured serially.
RESULTS: Four weeks after transplantation, blood samples revealed lower concentrations of IgG and IgA in the rituximab group than in the non-rituximab group. Neutrophil numbers did not fall below 0.5x10(9) /L four weeks or more after transplantation in the non-rituximab group. Neutrophil numbers dropped below 0.5x10(9) /L in 6 of 14 cases in the rituximab group.
CONCLUSION: Although the present study was retrospective and disease composition and pre-transplantation regimens differed between the two groups, the addition of rituximab to autologous transplantation might bring about a decrease of immunoglobulin levels and transient LON.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19122357     DOI: 10.2169/internalmedicine.48.1368

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  3 in total

1.  Drug-Induced Neutropenia: A Focus on Rituximab-Induced Late-Onset Neutropenia.

Authors:  Donald C Moore
Journal:  P T       Date:  2016-12

2.  Disseminated cryptococcosis in a non-Hodgkin's lymphoma patient with late-onset neutropenia following rituximab-CHOP chemotherapy: a case report and literature review.

Authors:  Yuji Hirai; Yusuke Ainoda; Takayo Shoji; Takahiro Fujita; Kentaro Yoshinaga; Masayuki Shiseki; Naoki Mori; Masanao Teramura; Kyoichi Totsuka; Toshiko Motoji
Journal:  Mycopathologia       Date:  2011-04-07       Impact factor: 2.574

3.  Long-term survey of survival time, histological transformation, and secondary malignancies in Japanese patients with advanced-stage follicular lymphoma in the rituximab era: Hokkaido Hematology Study Group.

Authors:  Yasuo Hirayama; Kunihiko Ishitani; Shuithi Ota; Mitsutoshi Kurosawa; Takeshi Kondo; Rishu Takimoto; Akio Mori; Hajime Sakai; Yoshihiro Torimoto; Satoshi Yamamoto; Kazuya Sato; Hiroshi Iwasaki; Kyuhei Kohda; Tadao Ishida; Yasuhiro Kakinoki; Takashi Fukuhara; Junji Kato
Journal:  Int J Hematol       Date:  2014-07-23       Impact factor: 2.490

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.